RxDoctor Payments Data

Pedro Garciarena, MD

Neurology · Naples, FLNPI 1508038431

Payments from drug & device makers

$13,681in general payments, 2019–2025

Across 607 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$836
  • Novartis$711
  • AstraZeneca$677
  • Amgen$654
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$1621%
  • Food & beverage$13,52099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.63$1,706
AbbVie(2 entities)106$1,648
Teva Pharmaceuticals USA, Inc.32$836
Novartis32$711
AstraZeneca(2 entities)19$677
Amgen(2 entities)31$654
Eisai Inc.18$643
Acorda Therapeutics, Inc15$390
Neurocrine Biosciences, Inc.14$367
Acadia Pharmaceuticals Inc18$363
Alnylam Pharmaceuticals Inc.12$310
Lilly USA, LLC18$293
Takeda Pharmaceuticals U.S.A., Inc.14$257
Biogen8$254
Scilex Pharmaceuticals Inc.11$254
Sunovion Pharmaceuticals Inc.18$249
Sanofi8$230
Amneal Pharmaceuticals LLC14$230
Pfizer13$223
SK Life Science, Inc.4$212
Lundbeck LLC8$196
Argenx US, Inc.9$190
Novocure Inc.2$183
Medtronic2$181
MDD US Operations, LLC10$171
GE HealthCare9$166
Avanir Pharmaceuticals, Inc.10$161
Neurelis, Inc.9$155
Bristol Myers Squibb7$139
Merz Pharmaceuticals, LLC5$136
Biohaven Pharmaceutical Holding Company Ltd.2$125
Greenwich Biosciences, Inc.1$121
Johnson & Johnson(2 entities)6$99
Sumitomo Pharma America, Inc.4$84
Xeris Pharmaceuticals, Inc.3$67
Kyowa Kirin, Inc.3$63
Biohaven Pharmaceuticals, Inc.4$63
Mallinckrodt Hospital Products Inc.3$63
Upsher-smith Laboratories LLC3$61
Vanda Pharmaceuticals Inc.3$60
Tanabe Pharma America, Inc.3$46
Otsuka America Pharmaceutical, Inc.2$45
Supernus Pharmaceuticals, Inc.3$44
Abbott2$44
Tersera Therapeutics LLC2$38
Aucta Pharmaceuticals, Inc.1$37
Averitas Pharma Inc.1$34
Impel Pharmaceuticals Inc.2$33
Jazz Pharmaceuticals Inc.2$30
GRT US Holding, Inc.1$26
Avion Pharmaceuticals1$24
Ipsen Biopharmaceuticals, Inc1$24
E.r. Squibb & Sons, L.L.C.1$24
Boston Scientific1$23
Grifols USA, LLC1$23
Ceribell, Inc.1$20
TG Therapeutics, Inc.1$19
Ironwood Pharmaceuticals, Inc1$19
Almatica Pharma LLC1$19
Redhill Biopharma Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,681 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$325,553
Medicare patients
365
Services billed
33,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate15$64,952
Aimovig AutoinjectorErenumab-Aooe45$58,488
LamictalLamotrigine11$32,016
Emgality PenGalcanezumab-Gnlm33$23,191
BotoxOnabotulinumtoxina15$20,189
QuliptaAtogepant17$18,216
RytaryCarbidopa/Levodopa25$17,578
Nurtec OdtRimegepant Sulfate12$14,671
Memantine Hcl ErMemantine Hcl53$6,319
Memantine Hcl220$5,696
Sumatriptan Succinate37$4,229
Levetiracetam73$3,118
Gabapentin268$2,961
Scopolamine21$2,805
Pregabalin84$2,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$363$64,95215 claims
AbbVieBotox, Qulipta$1,648$38,40532 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$230$19,89243 claims
PfizerNurtec Odt$223$14,67112 claims
Upsher-smith Laboratories LLCTopiramate$61$1,68694 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →